Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Lilly (ELI) & Co. (NYSE: LLY).

Full DD Report for LLY

You must become a subscriber to view this report.


Recent News from (NYSE: LLY)

Athenex's Oraxol shows encouraging action in early-stage gastric cancer study
Results from the second cohort in a Phase 1b clinical trial evaluating the combination of Athenex's Oraxol (oral paclitaxel plus HM3018A) and Eli Lilly's (NYSE: LLY ) Cyramza (ramucirumab) in treatment-resistant gastric cancer patients showed a positive effect. More news on: Eli Lilly a...
Source: SeekingAlpha
Date: December, 11 2018 08:19
Pfenex files U.S. marketing application for generic Forteo; shares up 5%
Thinly traded micro cap Pfenex ( PFNX +5.2% ) is up on light volume in early trade following its announcement that it has submitted its U.S. marketing application seeking approval for PF708, a generic version of Eli Lilly's ( LLY -0.9% ) osteoporosis med Forteo (teriparatide) which gen...
Source: SeekingAlpha
Date: December, 10 2018 09:55
Stocks To Watch: Tencent Music, Starbucks And Under Armour In Focus
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are prepping for another week of volatility as concerns over the China tr...
Source: SeekingAlpha
Date: December, 08 2018 09:31
Today's Research Reports on Trending Tickers: Eli Lilly and Company and AstraZeneca
NEW YORK, NY / ACCESSWIRE / December 5, 2018 / U.S. equities plunged on Tuesday as skepticism over the U.S. and China’s ability to close a trade agreement weighed on the markets. The Dow Jones Industrial Average fell 3.10 percent to close at 25,027.07, while the S&P 500 Index dec...
Source: ACCESSWIRE IA
Date: December, 05 2018 08:00
Biohaven Pharma up 17% on positive data on migraine med Zydis
Thinly traded Biohaven Pharmaceutical Holding Company ( BHVN +17.1% ) is up on more than double normal volume following its announcement of topline data from a Phase 3 clinical trial, BHV3000-303 , evaluating lead candidate Zydis (rimegepant) orally dissolving tablet for the acute treat...
Source: SeekingAlpha
Date: December, 03 2018 12:05
NCCN Oncology Research Program Awarded $2 Million from Lilly to Study Mechanisms of Resistance to CDK4 & 6 Inhibitors in Breast Cancer Treatment
PLYMOUTH MEETING, Pa. and INDIANAPOLIS , Dec. 3, 2018 /PRNewswire/ -- The National Comprehensive Cancer Network ® ( NCCN ® ) Oncology Research Program ( ORP ) announces plans to solicit and oversee research projects that evaluate cyclin dependent kinase (CDK)4 &...
Source: PR Newswire
Date: December, 03 2018 10:15
Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences - Discovering Underlying Factors of Influence
NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Virtu Financial, Inc. (NASDAQ:VIRT), Fate Therapeutics, Inc. (NASDAQ:FATE...
Source: GlobeNewswire
Date: December, 03 2018 07:40
Week In Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal With Zymeworks
Deals and Financings BeiGene (BGNE) (HKEX:06160) of Beijing announced cancer drug deals worth up to $1.3 billion with Vancouver's Zymeworks (ZYME) (see story ). BeiGene will acquire Asian rights to two bispecific antibodies from Zymeworks and will have rights to three to-be-discovered bispe...
Source: SeekingAlpha
Date: December, 02 2018 10:41
Trading Lesson- What to Know About Biotech, Gene & Therapies Ideas
Because of speculative market behavior, investing in early-stage biotechnology companies requires great skill and patience (luck is always helpful as well). Here are a dozen and a half stocks that investors and traders should know about, writes Monty Guild Thursday. The year 2018 has not b...
Source: MoneyShow.com
Date: November, 30 2018 10:08
Alkermes' ALKS 3831 successful in late-stage schizophrenia study; shares up 6% premarket
Alkermes plc (NASDAQ: ALKS ) announces positive topline results from a Phase 3 clinical trial, ENLIGHTEN-2 , evaluating orally administered ALKS 3831 (olanzapine/samidorphan) in patients with schizophrenia. More news on: Alkermes plc, Eli Lilly and Company, Healthcare stocks news, Stock...
Source: SeekingAlpha
Date: November, 29 2018 07:31

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-14106.16106.58106.71105.825,167,412
2017-09-2884.5985.0085.5884.152,840,987
2017-09-2784.3484.6584.8083.973,085,205
2017-09-2684.4384.2285.1384.012,347,234
2017-09-2583.8784.6484.6583.804,223,772

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1025,93296,25726.9404Cover
2018-12-075,00462,0458.0651Cover
2018-12-068,64679,98310.8098Cover
2018-12-0427,835120,24423.1488Cover
2018-12-0356,20992,27960.9120Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on LLY.


About Lilly (ELI) & Co. (NYSE: LLY)

Logo for Lilly (ELI) & Co. (NYSE: LLY)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $89,841,075,863 - 05/25/2018
  • Issue and Outstanding: 1,085,430,420 - 04/23/2018

 


Recent Filings from (NYSE: LLY)

Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: July, 27 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: July, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 24 2018
Amendment to a previously filed SC TO-T
Filing Type: SC TO-T/AFiling Source: edgar
Filing Date: June, 22 2018
An annual report of employee stock purchase savings and similar plans
Filing Type: 11-KFiling Source: edgar
Filing Date: June, 18 2018
Amendment to a previously filed SC TO-T
Filing Type: SC TO-T/AFiling Source: edgar
Filing Date: June, 15 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: June, 01 2018
Amendment to a previously filed SC TO-T
Filing Type: SC TO-T/AFiling Source: edgar
Filing Date: May, 30 2018
Tender offer schedule and amendment filed by a third party
Filing Type: SC TO-TFiling Source: edgar
Filing Date: May, 23 2018
Specialized Disclosure Report
Filing Type: SDFiling Source: edgar
Filing Date: May, 16 2018

 

 


Daily Technical Chart for (NYSE: LLY)

Daily Technical Chart for (NYSE: LLY)


Stay tuned for daily updates and more on (NYSE: LLY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: LLY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in LLY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of LLY and does not buy, sell, or trade any shares of LLY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/